OBJECTIVE: To determine influence of age and HIV infection on influenza vaccine responses. DESIGN: Evaluate serologic response to seasonal trivalent influenza vaccine (TIV) as the immunologic outcome in HIV-infected (HIV⁺) and age-matched HIV negative (HIV⁻) adults. METHODS: During 2013-2016, 151 virologically controlled HIV⁺ individuals on antiretroviral therapy and 164 HIV⁻ volunteers grouped by age as young (<40 years), middle aged (40-59 years) and old (≥60 years) were administered TIV and investigated for serum antibody response to vaccine antigens. RESULTS: At prevaccination (T0) titers were in seroprotective range in more than 90% of participants. Antibody titers increased in all participants postvaccination but frequency of classified vaccine responders to individual or all three vaccine antigens at 3-4 weeks was higher in HIV⁻ than HIV⁺ adults with the greatest differences manifesting in the young age group. Of the three vaccine strains in TIV, antibody responses at T2 were weakest against H3N2 with those to H1N1 and B antigens dominating. Among the age groups, the titers for H1N1 and B were lowest in old age, with evidence of an age-associated interaction in HIV⁺ persons with antibody to B antigen. CONCLUSION: Greater frequencies of vaccine nonresponders are seen in HIV⁺ young compared with HIV⁻ adults and the observed age-associated interaction for B antigen in HIV⁺ persons are supportive of the concept of premature immune senescence in controlled HIV infection. High-potency influenza vaccination recommended for healthy aging could be considered for HIV⁺ adults of all ages.
OBJECTIVE: To determine influence of age and HIV infection on influenza vaccine responses. DESIGN: Evaluate serologic response to seasonal trivalent influenza vaccine (TIV) as the immunologic outcome in HIV-infected (HIV⁺) and age-matched HIV negative (HIV⁻) adults. METHODS: During 2013-2016, 151 virologically controlled HIV⁺ individuals on antiretroviral therapy and 164 HIV⁻ volunteers grouped by age as young (<40 years), middle aged (40-59 years) and old (≥60 years) were administered TIV and investigated for serum antibody response to vaccine antigens. RESULTS: At prevaccination (T0) titers were in seroprotective range in more than 90% of participants. Antibody titers increased in all participants postvaccination but frequency of classified vaccine responders to individual or all three vaccine antigens at 3-4 weeks was higher in HIV⁻ than HIV⁺ adults with the greatest differences manifesting in the young age group. Of the three vaccine strains in TIV, antibody responses at T2 were weakest against H3N2 with those to H1N1 and B antigens dominating. Among the age groups, the titers for H1N1 and B were lowest in old age, with evidence of an age-associated interaction in HIV⁺ persons with antibody to B antigen. CONCLUSION: Greater frequencies of vaccine nonresponders are seen in HIV⁺ young compared with HIV⁻ adults and the observed age-associated interaction for B antigen in HIV⁺ persons are supportive of the concept of premature immune senescence in controlled HIV infection. High-potency influenza vaccination recommended for healthy aging could be considered for HIV⁺ adults of all ages.
Authors: Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: David Furman; Vladimir Jojic; Shalini Sharma; Shai S Shen-Orr; Cesar J L Angel; Suna Onengut-Gumuscu; Brian A Kidd; Holden T Maecker; Patrick Concannon; Cornelia L Dekker; Paul G Thomas; Mark M Davis Journal: Sci Transl Med Date: 2015-04-01 Impact factor: 17.956
Authors: Andrew M Gross; Philipp A Jaeger; Jason F Kreisberg; Katherine Licon; Kristen L Jepsen; Mahdieh Khosroheidari; Brenda M Morsey; Susan Swindells; Hui Shen; Cherie T Ng; Ken Flagg; Daniel Chen; Kang Zhang; Howard S Fox; Trey Ideker Journal: Mol Cell Date: 2016-04-21 Impact factor: 17.970
Authors: Carlos A DiazGranados; Andrew J Dunning; Murray Kimmel; Daniel Kirby; John Treanor; Avi Collins; Richard Pollak; Janet Christoff; John Earl; Victoria Landolfi; Earl Martin; Sanjay Gurunathan; Richard Nathan; David P Greenberg; Nadia G Tornieporth; Michael D Decker; H Keipp Talbot Journal: N Engl J Med Date: 2014-08-14 Impact factor: 91.245
Authors: Christoph G Lange; Michael M Lederman; Kathy Medvik; Robert Asaad; Mary Wild; Robert Kalayjian; Hernan Valdez Journal: AIDS Date: 2003-09-26 Impact factor: 4.177
Authors: Monty Montano; Shalender Bhasin; Richard T D'Aquila; Kristine M Erlandson; William J Evans; Nicholas T Funderburg; Amy Justice; Lishomwa C Ndhlovu; Bisola Ojikutu; Marco Pahor; Savita Pahwa; Alice S Ryan; Jennifer Schrack; Michael B Schultz; Paola Sebastiani; David A Sinclair; Julia Tripp; Bruce Walker; Julie A Womack; Raymond Yung; R Keith Reeves Journal: AIDS Res Hum Retroviruses Date: 2019-09-23 Impact factor: 2.205
Authors: Janko Nikolich-Žugich; Christine M Bradshaw; Jennifer L Uhrlaub; Makiko Watanabe Journal: Curr Opin Virol Date: 2020-11-04 Impact factor: 7.090
Authors: Lesley R de Armas; Suresh Pallikkuth; Li Pan; Stefano Rinaldi; Nicola Cotugno; Sarah Andrews; Rajendra Pahwa; Adrian B McDermott; Paolo Palma; Savita Pahwa Journal: Sci Rep Date: 2019-02-21 Impact factor: 4.379
Authors: Erin E Sundermann; Kristine M Erlandson; Caitlin N Pope; Anna Rubtsova; Jessica Montoya; Alison A Moore; Catia Marzolini; Kelly K O'Brien; Savita Pahwa; Brendan A I Payne; Leah H Rubin; Sharon Walmsley; Norman J Haughey; Monty Montano; Maile Y Karris; Joseph B Margolick; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2019-09-10 Impact factor: 1.723
Authors: Dana Gabuzda; Beth D Jamieson; Ronald G Collman; Michael M Lederman; Tricia H Burdo; Steven G Deeks; Dirk P Dittmer; Howard S Fox; Nicholas T Funderburg; Savita G Pahwa; Ivona Pandrea; Cara C Wilson; Peter W Hunt Journal: Pathog Immun Date: 2020-06-17